Neurologic clinics
-
The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life. Unfortunately, many patients continue to experience refractory epilepsy despite the use of these new agents, and dose-related adverse effects and idiosyncratic reactions continue to be problematic. A recent report describes six new compounds in preclinical development, and five in clinical trials [131]. ⋯ These include: choosing the drug appropriate for the epileptic syndrome, assessing accurately the range of a drug's adverse effects in an individual patient, and considering carefully the drug's interactions in combination drug therapy. In considering drug combinations, differing mechanisms of drug action and favorable pharmacodynamic interactions (an area requiring additional studies) are of importance. Clinicians caring for children who have epilepsy anticipate further advances in the pharmacogenetics and molecular pathophysiology of epilepsy, leading to individually tailored, effective, and safe therapy.
-
The presurgical evaluation should result in a clear understanding of whether surgery can be undertaken and its associated risks and potential for benefit. The results of surgery are best when there is congruence in the seizure semiology, the irritative zone on interictal EEG, and the ictal onset zone with the epileptogenic lesion as defined on MRI and PET, and when there is a clear understanding of the ictal onset zone's relationship to eloquent cortex as defined by neuropsychologic evaluation, the intracarotid amobarbital test, and cortical functional mapping.